B

Bright Minds Biosciences Inc
CNSX:DRUG

Watchlist Manager
Bright Minds Biosciences Inc
CNSX:DRUG
Watchlist
Price: 56.3 CAD -8.25% Market Closed
Market Cap: 251.3m CAD
Have any thoughts about
Bright Minds Biosciences Inc?
Write Note

Intrinsic Value

DRUG's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one DRUG stock under the Base Case scenario is 4.43 CAD. Compared to the current market price of 56.3 CAD, Bright Minds Biosciences Inc is Overvalued by 92%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DRUG Intrinsic Value
4.43 CAD
Overvaluation 92%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bright Minds Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DRUG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DRUG?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Bright Minds Biosciences Inc

Provide an overview of the primary business activities
of Bright Minds Biosciences Inc.

What unique competitive advantages
does Bright Minds Biosciences Inc hold over its rivals?

What risks and challenges
does Bright Minds Biosciences Inc face in the near future?

What significant events have occurred
in Bright Minds Biosciences Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bright Minds Biosciences Inc.

Provide P/S
for Bright Minds Biosciences Inc.

Provide P/E
for Bright Minds Biosciences Inc.

Provide P/OCF
for Bright Minds Biosciences Inc.

Provide P/FCFE
for Bright Minds Biosciences Inc.

Provide P/B
for Bright Minds Biosciences Inc.

Provide EV/S
for Bright Minds Biosciences Inc.

Provide EV/GP
for Bright Minds Biosciences Inc.

Provide EV/EBITDA
for Bright Minds Biosciences Inc.

Provide EV/EBIT
for Bright Minds Biosciences Inc.

Provide EV/OCF
for Bright Minds Biosciences Inc.

Provide EV/FCFF
for Bright Minds Biosciences Inc.

Provide EV/IC
for Bright Minds Biosciences Inc.

Show me price targets
for Bright Minds Biosciences Inc made by professional analysts.

Compare the intrinsic valuations
of Bright Minds Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bright Minds Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bright Minds Biosciences Inc compared to its peers.

Compare the P/E ratios
of Bright Minds Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Bright Minds Biosciences Inc with its peers.

Analyze the financial leverage
of Bright Minds Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Bright Minds Biosciences Inc.

Provide ROE
for Bright Minds Biosciences Inc.

Provide ROA
for Bright Minds Biosciences Inc.

Provide ROIC
for Bright Minds Biosciences Inc.

Provide ROCE
for Bright Minds Biosciences Inc.

Provide Gross Margin
for Bright Minds Biosciences Inc.

Provide Operating Margin
for Bright Minds Biosciences Inc.

Provide Net Margin
for Bright Minds Biosciences Inc.

Provide FCF Margin
for Bright Minds Biosciences Inc.

Show all solvency ratios
for Bright Minds Biosciences Inc.

Provide D/E Ratio
for Bright Minds Biosciences Inc.

Provide D/A Ratio
for Bright Minds Biosciences Inc.

Provide Interest Coverage Ratio
for Bright Minds Biosciences Inc.

Provide Altman Z-Score Ratio
for Bright Minds Biosciences Inc.

Provide Quick Ratio
for Bright Minds Biosciences Inc.

Provide Current Ratio
for Bright Minds Biosciences Inc.

Provide Cash Ratio
for Bright Minds Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Bright Minds Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Bright Minds Biosciences Inc?

What is the current Free Cash Flow
of Bright Minds Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bright Minds Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bright Minds Biosciences Inc

Current Assets 6.3m
Cash & Short-Term Investments 6.2m
Receivables 17.2k
Other Current Assets 58.3k
Non-Current Assets 12.1k
PP&E 12.1k
Other Non-Current Assets -10
Current Liabilities 178.6k
Accounts Payable 149.6k
Accrued Liabilities 15k
Other Current Liabilities 14k
Efficiency

Earnings Waterfall
Bright Minds Biosciences Inc

Revenue
0 CAD
Operating Expenses
-3.6m CAD
Operating Income
-3.6m CAD
Other Expenses
41.6k CAD
Net Income
-3.6m CAD

Free Cash Flow Analysis
Bright Minds Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DRUG Profitability Score
Profitability Due Diligence

Bright Minds Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

45/100
Profitability
Score

Bright Minds Biosciences Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

DRUG Solvency Score
Solvency Due Diligence

Bright Minds Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Bright Minds Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DRUG Price Targets Summary
Bright Minds Biosciences Inc

There are no price targets for DRUG.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DRUG?

Click here to dive deeper.

Dividends

Bright Minds Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DRUG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

DRUG News

Profile

Bright Minds Biosciences Inc

Country

Canada

Industry

Biotechnology

Market Cap

251.3m CAD

Dividend Yield

0%

Description

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in developing therapeutics to improve the lives of patients with severe and life-altering diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-02-08. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy and pain. The firm has a portfolio of serotonin agonists designed to target neurocircuit abnormalities to treat disorders, such as resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. The company is focused on developing a line of serotonergic 5-Hydroxytryptamine (5-HT) drug candidates that target the 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C receptors. Its offers 5-HT2C for the treatment of dravet syndrome and behavioral disorders. Its offers 5-HT2A for treatment of depression and other neuropsychiatric disorders. Its offers 5-HT2A + 5-HT2C for several chronic pain disorders/neuropathic pain syndromes, including cluster headaches and chemotherapy-induced peripheral neuropathy.

Contact

BRITISH COLUMBIA
Vancouver
1500 - 1055 West Georgia St.
+16474072515.0
brightmindsbio.com

IPO

2021-02-08

Employees

-

Officers

Co-Founder, CEO, President & Director
Mr. Ian McDonald
Chief Financial Officer
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA
Chief Science Officer & Director
Dr. Jan Torleif Pedersen M.Sc., Ph.D.
Chief Medical Officer
Dr. Mark A. Smith M.D., Ph.D.
COO & VP of Corporate Development
Mr. Alex Vasilkevich
Consultant
Dr. Emer Leahy M.B.A., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one DRUG stock?

The intrinsic value of one DRUG stock under the Base Case scenario is 4.43 CAD.

Is DRUG stock undervalued or overvalued?

Compared to the current market price of 56.3 CAD, Bright Minds Biosciences Inc is Overvalued by 92%.

Back to Top